Document information
- University
- Politecnico di Milano
- Degree programme
- Biomedical Engineering
- Subject
- Technology for Regenerative Medicine
- Classification
- Other study material
- Original format
- Text
- Searchable text
← Back
Other
Tabella med riassuntiva
University study material for Technology for Regenerative Medicine in the Biomedical Engineering degree programme at Politecnico di Milano. The document covers: Cell source Cell type/s Advantages Criticalities Can be used? Autologous ___ isolated from patient and expanded Immune-compatible - Limited availability - Limited expandability - Invasive test - Risk of tumor (MSC) Y N (if cell patients are compromised) Autologous iPS from
Technology for Regenerative MedicineOther
Document information
What's included in this study material
University study material for Technology for Regenerative Medicine in the Biomedical Engineering degree programme at Politecnico di Milano. The document covers: Cell source Cell type/s Advantages Criticalities Can be used? Autologous ___ isolated from patient and expanded Immune-compatible - Limited availability - Limited expandability - Invasive test - Risk of tumor (MSC) Y N (if cell patients are compromised) Autologous iPS from
Import quality: text was extracted directly from the original document.
Extracted content from the document
Representative passages recognised in different parts of the material. The full extracted text remains available to search, while this compact preview makes the page easier to read.
Page 1
Cell source Cell type/s Advantages Criticalities Can be used? Autologous ___ isolated from patient and expanded Immune-compatible - Limited availability - Limited expandability - Invasive test - Risk of tumor (MSC) Y N (if cell patients are compromised) Autologous iPS from somatic cells of the patient and re- differentiated in ___ Immune-compatible - Risk of teratoma - Few protocols in re-differentation Y N (look at risk/benefit respect conventional therapy) Syngeneic Embryonic stem cells isolated from clones of the patient itself, and re-differentiated in ___ Immune-compatible (except for the mitochondrial DNA) - Risk of teratoma - Limitations of: ethical, technical and regulatory - Few protocols in re-differentation Y N (look at risk/benefit respect conventional therapy) Allogeneic (Stem cells/somatic cells) isolated from human donor and expanded - Available - Can be industrialized - Immunogenic - Risk of infection - Risk of tumor (MSC, multipotent cell) Y N (look at risk/benefit respect conventional therapy) Xenogeneic (Stem cells/somatic cells) isolated from non-human donor and expanded - Largely available from animal livestock - Can be industrialized - Acute immune rejection - Transmission of xeno-zoonoses - Limited biological functionality - Risk of tumor (MSC, multipotent cell) Y (if the patient is critical conditions and no other options) N
Preview
First page of the document.